Johnson Investment Counsel Inc. increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,017 shares of the company’s stock after acquiring an additional 265 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in AstraZeneca were worth $359,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Jennison Associates LLC grew its position in AstraZeneca by 34.7% in the 2nd quarter. Jennison Associates LLC now owns 21,807,209 shares of the company’s stock valued at $1,560,742,000 after buying an additional 5,617,054 shares during the last quarter. GQG Partners LLC boosted its position in shares of AstraZeneca by 25.3% during the 1st quarter. GQG Partners LLC now owns 21,545,387 shares of the company’s stock worth $1,495,465,000 after purchasing an additional 4,348,916 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of AstraZeneca by 272.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,572,966 shares of the company’s stock worth $120,415,000 after purchasing an additional 4,077,583 shares in the last quarter. Norges Bank purchased a new stake in shares of AstraZeneca during the 4th quarter worth $254,290,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of AstraZeneca by 407.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,093,345 shares of the company’s stock worth $271,553,000 after purchasing an additional 3,286,137 shares in the last quarter. 15.68% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Price Performance
AstraZeneca stock opened at $63.79 on Tuesday. AstraZeneca PLC has a 52 week low of $61.73 and a 52 week high of $76.56. The company has a quick ratio of 0.60, a current ratio of 0.79 and a debt-to-equity ratio of 0.60. The firm’s 50-day simple moving average is $65.71 and its 200 day simple moving average is $68.88. The firm has a market capitalization of $197.74 billion, a PE ratio of 33.57, a P/E/G ratio of 1.28 and a beta of 0.51.
Wall Street Analysts Forecast Growth
Several brokerages have commented on AZN. Jefferies Financial Group upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Monday, September 25th. Erste Group Bank restated a “hold” rating on shares of AstraZeneca in a research report on Friday, September 8th. Finally, StockNews.com assumed coverage on shares of AstraZeneca in a research report on Thursday, October 5th. They set a “strong-buy” rating on the stock. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $103.00.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Five stocks we like better than AstraZeneca
- How to Use the MarketBeat Stock Split Calculator
- Safeguard your portfolio with these three bargain stocks
- What is a Secondary Public Offering? What Investors Need to Know
- Membership clubs gain leverage for the consumer rebound
- Where to Find Earnings Call Transcripts
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.